<DOC>
	<DOCNO>NCT00001282</DOCNO>
	<brief_summary>This study evaluate long-term toxicity obtain preliminary information long-term efficacy combination antiretroviral therapy interleukin-2 ( IL-2 ) , cytokine immunomodulatory property . Currently 73 patient approve receive IL-2 start dose 18 MIU/d 5 day . Multiple course IL-2 administer , approximately 2 month interval . Clinical , laboratory , immunologic , viral parameter closely monitor time evidence toxicity preliminary evidence efficacy .</brief_summary>
	<brief_title>A Phase I/II Study Combination Azidothymidine Interleukin-2 ( IL-2 ) Treatment HIV-Infected Patients</brief_title>
	<detailed_description>This study evaluate long-term toxicity obtain preliminary information long-term efficacy combination antiretroviral therapy interleukin-2 ( IL-2 ) , cytokine immunomodulatory property . Currently 73 patient approve receive IL-2 start dose 18 MIU/d 5 day . Multiple course IL-2 administer , approximately 2 month interval . Clinical , laboratory , immunologic , viral parameter closely monitor time evidence toxicity preliminary evidence efficacy .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<criteria>Laboratory value Grade 0 1 . Hemoglobin great 9 g/dl ; neutrophil count great 1,000 cells/mm ( 3 ) permit patient CD4 count 200 cells/mm ( 3 ) . No therapy corticosteroid , chemotherapy , experimental therapy IL2 prior 4 week . Willing able take AZT . Therapy dideoxyinosine dideoxycytidine permit . Any approved antiretroviral drug administer , either alone combination . Delavirdine ( U90152S ) , 400 mg tid , permit antiretroviral agent , either alone combination currently approve antiretroviral agent . Patients must malignancy Kaposi sarcoma . Patient must concurrent opportunistic infection oropharyngeal candidiasis HSV . Patients may CD4 count le 200 cells/mm ( 3 ) concurrent opportunistic infection , patient must respond least 2 week therapy effective therapy available . Patients must abuse substance . Patients must significant cardiac , pulmonary , rheumatologic , autoimmune , CNS disease . Home patient must enrol good stand current NIAID protocol involve use IL2 therapy . The patient must already undergo least one year treatment protocol IL2 therapy give , include least 2 welltolerated outpatient cycle scIL2 stable dose . Home The patient must history generally tolerable side effect receive IL2 require frequent medical intervention , intravenous fluid replacement , and/or IL2 dose reduction . Conditions generally suitable home scIL2 administration would include ( limited ) unusually heavy requirement narcotic usage cycle , significant urticaria ( hive ) allergic condition , history possible airway compromise due throat swell . Home Patient must experience serious ( grade 3 high ) clinical laboratory abnormality medical significance day 05 last 2 outpatient scIL2 cycle . Home The patient must strong relationship private physician healthcare provider home demonstrate close involvement patient 's care date would willing help supervise patient 's care home scIL2 cycle . Because need identify single healthcare provider home agree available render care ( need ) patient 's scIL2 cycle , patient currently receive home care rotate staff member general clinic setting may eligible home scIL2 administration . A signed write statement acknowledge willingness participate monitoring must receive clinic 8 study team private physician healthcare provider prior first home scIL2 cycle . In addition , communication must occur clinic 8study team designate physician healthcare provider prior subsequent cycle confirm individual 's continued willingness serve onsite provider serious medical condition might develop cycle . Home The patient must live home address easy access telephone must demonstrate reliability respond telephone call clinic 8 staff member . The patient must also able provide study team reliable contact information close family member friend agree serve capacity `` caregiver '' cycle : i.e . someone able render nonmedical assistance patient able check condition daily event emergency medical assistance need summon . It become patient 's responsibility ensure local `` caregiver '' communicate willingness serve capacity telephone clinic 8study team prior cycle . Home The patient must `` reasonable '' ( i.e . rapid close ) access home emergency medical service nearby medical facility event medical crisis . The suitability athome situation assess casebycase basis clinic 8study team . Home The patient must demonstrate reliability consistency sterile technique , reconstitution IL2 vial , administration scIL2 injection . Home The patient must receive outpatient scIL2 cycle least every 6 month part normal protocol participation , except discretion study team . Home The patient must access reliable home weight scale able weigh accurately daily basis purpose safety monitoring .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2002</verification_date>
	<keyword>HIV</keyword>
	<keyword>Immunomodulator</keyword>
	<keyword>Anti-Viral</keyword>
</DOC>